Stock of the Day

December 31, 2021

Sotera Health (SHC)

$17.42
-$0.33 (-1.9%)
Market Cap: $5.06B

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Today's Trend

Sotera Health (NASDAQ: SHC) — shares are trading higher today after stronger-than-expected Q1 results, a confirmed FY‑2026 outlook and positive analyst support. Key near-term drivers: a revenue and EPS beat for Q1, management reaffirming guidance, and Piper Sandler keeping an Overweight stance (with a lowered but still-elevated $22 price target). Investors should like the top-line momentum and margin expansion, but watch leadership transition and leverage/valuation risks.

  • Q1 results beat and outlook reaffirmed — Sotera reported Q1 revenue up ~10% to $280.1M, adjusted EPS of $0.18 (vs. $0.17 consensus) and raised adjusted EBITDA and margin commentary; the company reaffirmed FY‑2026 guidance (5.0%–6.5% revenue growth; 5.5%–7.0% Adj. EBITDA growth) — this is the main catalyst behind today's rally. Article
  • Analyst support maintained — Piper Sandler reaffirmed an Overweight rating and set a $22 price target (down from $24), implying substantial upside from current levels; continued analyst backing helps sustain investor confidence. Article
  • Earnings-call tone and coverage — management set a “steady growth” tone on the Q1 call and analysts/media are highlighting momentum and margin improvement; full call transcript and highlights available for detail if you want to probe segment performance and backlog. TipRanks summary
  • Broader press and transcript coverage — Seeking Alpha, Yahoo Finance and other outlets published the Q1 transcript/recap and noted the revenue/EPS beats and stock reaction; useful for drilling into management commentary and segment KPIs. Seeking Alpha transcript
  • Leadership transition introduces near-term uncertainty — Sotera announced a planned CEO transition (new CEO Alton Shader effective May 26; current CEO to become Executive Chairman). It's orderly but any management change can create execution risk until the new CEO is fully in place. Article

Investor takeaway: near-term upside is being driven by tangible beat-and-reaffirm results plus analyst support. If you hold or are considering a position, focus on upcoming quarterly cadence, execution under the new CEO, and how free cash flow / leverage evolve given the company's relatively elevated debt metrics.

← Previous Stock of the DayNext Stock of the Day →